To view the enriched version of this site, you must enable JavaScript in your browser.
Definitive outcomes of radiofrequency ablation for Barrett’s esophagus using the HALO ablation system reported at the Digestive Disease Week meeting for gastroenterologists and esophageal surgeons
Researchers present safety and efficacy results of 429 patients treated with radiofrequency ablation for pre-cancerous Barrett’s esophagus
Study in the New England Journal of Medicine shows non-surgical treatment for pre-cancerous condition of esophagus is effective and reduces risk for cancer development
Multi-centre European clinical trial shows advanced dysplasia and early cancer of esophagus cured with combined endoscopic resection and radiofrequency ablation with HALO ablation system
Precancerous esophagus disease eliminated in 98.4% of patients treated with HALO Ablation System
Early esophageal cancer and pre-cancer eliminated with non-surgical treatment combination
The Wall Street Journal - Esophageal Therapy You Can Stomach
Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
New study reports that ablative therapy with HALO360 device effectively treats highest-risk category of Barrett’s esophagus
Complications From Heartburn on the Rise
Presentation of Long-term Results for Treating Barrett’s Esophagus with HALO Ablation System
Genetic Abnormalities Associated with Esophageal Cancer Eliminated after Treatment with HALO Ablation System (Presented by Jacques Bergman, MD 2007 Digestive Disease Week)
Publication of Long-term Results for Treating Barrett’s Esophagus with HALO360 Ablation System
BÂRRX Medical, Inc. Secures $27.8 Million Series C Venture Funding
Nine Clinical Studies Evaluating Safety and Efficacy of HALO360 and HALO90 Systems to Treat Barrett's Esophagus Presented at Digestive Disease Week
BÂRRX Medical, Inc. Announces FDA Clearance of the HALO90 System
Investigators To Present Positive Clinical Trial Results Underscoring the Efficacy of BÂRRX Medical's Ablation Systems for Barrett's Esophagus
BÂRRX Medical, Inc. Acquires Intellectual Property Rights for Barrett's Esophagus, Expands Portfolio
BÂRRX Medical, Inc. Initiates Landmark Study Comparing Two Treatment Options for Barrett's Esophagus
BÂRRX Medical, Inc. Introduces New Minimally Invasive Tool for Treating Barrett's Esophagus
Surgical Endoscopy Publishes Data Evaluating Dosing and Ablation Depth of the HALO360 System in the Human Esophagus: A Technology Relevant as a Current Treatment for Barrett's Esophagus
Professional Society Urges Certain Patients with Chronic GERD to Seek Screening for Barrett's Esophagus
Data Evaluating Safety and Efficacy of the HALO360 System in Treating Barrett's Esophagus Presented at the American College of Gastroenterology Annual Meeting
Data Evaluating Safety and Efficacy of the HALO360 System in Treating Barrett's Esophagus
